Compare CTSO & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTSO | GNTA |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.9M | 41.7M |
| IPO Year | N/A | 2021 |
| Metric | CTSO | GNTA |
|---|---|---|
| Price | $0.70 | $1.62 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.38 | N/A |
| AVG Volume (30 Days) | ★ 119.9K | 103.9K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,979,520.00 | N/A |
| Revenue This Year | $9.51 | N/A |
| Revenue Next Year | $24.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.89 | N/A |
| 52 Week Low | $0.60 | $1.35 |
| 52 Week High | $1.61 | $10.00 |
| Indicator | CTSO | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 34.62 |
| Support Level | $0.66 | $1.80 |
| Resistance Level | $0.76 | $2.07 |
| Average True Range (ATR) | 0.07 | 0.17 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 6.57 | 3.33 |
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.